Synergistic Effects of Ginsenoside Rb1 and Peroxiredoxin 6 in Enhancing Myocardial Injury Treatment through Anti-Inflammatory, Anti-Oxidative, and Anti-Apoptotic Mechanisms DOI Creative Commons
Runhong Mu, Yupeng Li, Yunhe Cui

и другие.

Journal of Ginseng Research, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Ginsenosides have notable bioactivity in treating cardiovascular diseases, but the mechanisms of their combined use with Peroxiredoxin 6 (PRDX6) myocardial injury remain unclear. This study explores synergistic effects Ginsenoside Rb1 (Gs-Rb1) and PRDX6, aiming to provide a theoretical foundation for therapeutic potential. We established rat model isoproterenol (ISO)-induced observed that combination therapy was more effective than single-drug treatments, as shown by ECG monitoring Masson staining. performed RNA sequencing (RNA-Seq) on group ISO group. The results indicated that, compared group, alleviated reducing inflammation, oxidative stress, apoptosis. Further analyses, including cell morphology, apoptosis rates, HE staining, ROS fluorescence intensity, inflammation-related proteins, confirmed successfully inhibited apoptosis, managed lessened inflammation. Combined treatment Gs-Rb1 PRDX6 significantly cardiac tissue fibrosis rats, leading marked decrease serum CK LDH levels. RNA-seq analysis revealed upregulated genes related lipid metabolism small molecule biosynthesis, while downregulated were associated Validation experiments treatment's significant inhibition activity, These support effectiveness two-drug suppressing key biological processes tissue, suggesting potential combating fibrosis. clarifies how work together protect against damage, demonstrating reduces stress. highlights new avenue developing ginseng-based treatments.

Язык: Английский

Overview of Panax ginseng and its active ingredients protective mechanism on cardiovascular diseases DOI

Ziwei Zhou,

Meijing Li,

Zekuan Zhang

и другие.

Journal of Ethnopharmacology, Год журнала: 2024, Номер 334, С. 118506 - 118506

Опубликована: Июль 2, 2024

Язык: Английский

Процитировано

8
Ginsenoside Rh2(S) maintains cytoskeleton homeostasis and inhibits pyroptosis to resist cisplatin-induced cardiotoxicity through FGFR1/HRAS axis DOI

Hongbo Teng,

Shuai Huang,

Xialin Sun

и другие.

Phytomedicine, Год журнала: 2025, Номер 138, С. 156425 - 156425

Опубликована: Янв. 24, 2025

Язык: Английский

Процитировано

1
Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? DOI Creative Commons
Milton Packer

European Journal of Heart Failure, Год журнала: 2023, Номер 25(12), С. 2130 - 2143

Опубликована: Окт. 25, 2023

The active ingredients in many traditional Chinese medicines are isoprene oligomers with a diterpenoid or triterpenoid structure, which exert cardiovascular effects by signalling through nutrient surplus and deprivation pathways. Qiliqiangxin (QLQX) is commercial formulation of 11 different plant ingredients, whose compounds include astragaloside IV, tanshione IIA, ginsenosides (Rb1, Rg1 Re) periplocymarin. In the QUEST trial, QLQX reduced combined risk death heart failure hospitalization (hazard ratio 0.78, 95% confidence interval 0.68-0.90), based on 859 events 3119 patients over median 18.2 months; benefits were seen taking foundational drugs except for sodium-glucose cotransporter 2 (SGLT2) inhibitors. Numerous experimental studies diverse cardiac injuries have yielded highly consistent findings. marked abrupt injury, mitigated injury upregulating PI3K/Akt/mTOR/HIF-1α/NRF2 pathway; abrogated suppression PI3K, Akt, mTOR, HIF-1α NRF2. contrast, prolonged measured stress (as chronic failure), ameliorated oxidative stress, maladaptive hypertrophy, cardiomyocyte apoptosis, proinflammatory profibrotic pathways, while enhancing mitochondrial health promoting glucose fatty acid oxidation ATP production. These achieved an action to upregulate SIRT1/AMPK/PGC-1α enhanced autophagic flux. particular, appears enhance interaction PGC-1α PPARα, possibly direct binding RXRα; silencing SIRT1, RXRα favourable heart. Since PGC-1α/RXRα also downstream effector Akt/mTOR signalling, actions may explain its both acute stress. Intriguingly, individual - ginsenosides, IIA share QLQX's PGC-1α/RXRα/PPARα signalling. QXQL contains periplocymarin, glycoside that inhibits Na

Язык: Английский

Процитировано

16
Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential DOI Creative Commons
Jiaxu Liu, Guangxu Xiao,

Yujuan Liang

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2024, Номер 11

Опубликована: Янв. 24, 2024

Diagnosis and treatment of patients with cardiovascular neurologic diseases primarily focus on the heart brain, respectively. An increasing number preclinical clinical studies have confirmed a causal relationship between brain diseases. Cardiogenic dementia is cognitive impairment caused by dysfunction has received research attention. The prevention cardiogenic are essential to improve quality life, particularly in elderly aging population. This study describes changes function associated coronary artery disease, myocardial infarction, failure, atrial fibrillation valve disease. updated understanding two known pathogenic mechanisms presented discussed. One cascade events cerebral hypoperfusion due long-term reduction cardiac output after other regardless blood flow injury. Furthermore, potential medications for reviewed, particular attention multicomponent herbal medicines.

Язык: Английский

Процитировано

7
Cinnamaldehyde activates AMPK/PGC-1α pathway via targeting GRK2 to ameliorate heart failure DOI

Zhanchi Xu,

Minghui Li,

Dongxin Lyu

и другие.

Phytomedicine, Год журнала: 2024, Номер 133, С. 155894 - 155894

Опубликована: Июль 20, 2024

Язык: Английский

Процитировано

5
Ginsenoside Rb1 in cardiovascular and cerebrovascular diseases: A review of therapeutic potentials and molecular mechanisms DOI Open Access
Y Song, Chen Chen,

Wei Li

и другие.

Chinese Herbal Medicines, Год журнала: 2024, Номер 16(4), С. 489 - 504

Опубликована: Сен. 16, 2024

Язык: Английский

Процитировано

5
Investigating the therapeutic potential of terpene metabolites in hot-natured herbal medicines and their mechanistic impact on circulatory disorders DOI

Huong-Giang Le,

Thanh Hao Huynh,

Bo‐Rong Peng

и другие.

Phytochemistry Reviews, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Natural products and ferroptosis: A novel approach for heart failure management DOI
Zeyu Zhang, Zhihua Yang, Shuai Wang

и другие.

Phytomedicine, Год журнала: 2025, Номер unknown, С. 156783 - 156783

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Therapeutic Potential of Ginsenoside Rb1-PLGA Nanoparticles for Heart Failure Treatment via the ROS/PPARα/PGC1α Pathway DOI Creative Commons

Lixin Du,

Huiling Lu,

Ziyan Wang

и другие.

Molecules, Год журнала: 2023, Номер 28(24), С. 8118 - 8118

Опубликована: Дек. 15, 2023

(1) Background: Ginsenoside Rb1-PLGA nanoparticles (GRb1@PLGA@NPs) represent a novel nanotherapeutic system, yet their therapeutic efficacy and underlying mechanisms for treating heart failure (HF) remain unexplored. This study aims to investigate the potential effects of GRb1@PLGA@NPs in HF treatment; (2) Methods: The left anterior descending coronary artery ligation was employed establish model Sprague-Dawley rats, along with an vitro oxidative stress using H9c2 myocardial cells. Following treatment GRb1@PLGA@NPs, cardiac tissue pathological changes cell proliferation were observed. Additionally, serum levels biomarkers such as NT-proBNP, TNF-α, IL-1β measured, expression ROS/PPARα/PGC1α pathway; (3) Results: effectively ameliorated status tissues mitigated stress-induced damage, elevated SOD MMP levels, reduced LDH, MDA, ROS, levels. Furthermore, PPARα PGC1α proteins upregulated; (4) Conclusions: may attenuate injury treat through pathway.

Язык: Английский

Процитировано

9
Effects of Shenmai injection against chronic heart failure: a meta-analysis and systematic review of preclinical and clinical studies DOI Creative Commons
Yang Wu, Tianli Li,

Pochen Li

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 14

Опубликована: Фев. 6, 2024

Objective: This study aims to evaluate the clinical and preclinical efficacy of SMI in treating CHF, summarize relevant mechanisms action order provide evidence for its role CHF treatment. Methods: A systematic computerized search eight databases three registry systems was performed, with time frame spanning from inception 30 June 2023. Strict procedures were used data extraction, quality assessment, analysis. The methodological included studies assessed using RoB-2 SYRCLE tools. Statistical analysis performed Rev Man 5.4 software, either fixed-effects or random-effects models. Results: total 25 trials (including test group 1,367 patients, control 1,338 patients) 11 animal 201 animals) this review. meta-analysis showed that can improve cardiac function indicators (LVEF, LVFS, LVEDV, LVESV, LVEDD, LVESD) (p < 0.00001), reduce BNP/NT-proBNP levels 0.01), inflammatory markers (hs-CRP, TNF-α, IL-6) 0.00001) endothelin (ET) 0.0001). In studies, demonstrated improved LVFS) 0.05), heart failure (NT-proBNP, p 0.05) when compared groups. Conclusion: represents first which includes both on SMI. Clinical have shown patients through anti-apoptotic effects, antioxidant activities, anti-inflammatory improvement myocardial metabolism. has certain limitations terms literature quality, quantity, follow-up time. Therefore, conclusions drawn may require further validation larger-scale, high-quality RCT trials.

Язык: Английский

Процитировано

3